profit from every $100 of sales.
$0$100
Fulgent Genetics
$24.66-0.76% today
-16.7% in 1 year
1-year low $13.791-year high $30.85
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Fulgent Genetics sold, what it kept, and what it did with the cash.
Sales went from $619 million in 2022 to $323 million in 2025, with -$60.5 million of profit last year.
SalesProfit
Fulgent Genetics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Fulgent Genetics | No profit yet | ||
 Illumina | 36.8× · Expensive | ||
 Labcorp Holdings | 34.3× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Guardant Health | No profit yet |
AI analysis
An AI analyst reads Fulgent Genetics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 619 | 289 | 283 | 323 | |
| 367 | 104 | 107 | 131 | |
| 182 | -75 | -74 | -91 | |
| 218 | -147 | -49 | -46 | |
| 143 | -168 | -43 | -61 | |
| 4.63 | -5.63 | -1.41 | -1.97 | |
| 59.3% | 36.1% | 37.8% | 40.6% | |
| 29.3% | -26.0% | -26.1% | -28.2% | |
| 23.2% | -58.0% | -15.1% | -18.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,386 | 1,235 | 1,220 | 1,214 |
| Cash | 80 | 97 | 55 | 50 |
| Total debt | 39 | 15 | 8 | 8 |
| Total liabilities | 116 | 102 | 91 | 107 |
| 1,267 | 1,136 | 1,133 | 1,112 | |
| 31 | 30 | 30 | 31 | |
| 11.2% | -11.9% | -5.1% | -4.9% | |
| 11.3% | -14.8% | -3.8% | -5.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 254 | 27 | 21 | -102 | |
| 19 | 22 | 40 | 23 | |
| 235 | 5 | -19 | -124 | |
| Dividends paid | – | – | – | – |
| 76 | 28 | 3 | 14 | |
| 33 | 43 | 44 | 40 |
Valuation
- –
- –
- –
- 0.5×
- 2.1×
- –
- –
- -18.0%
- -8.8%
- 0.0%
Profitability
- 40.6%
- -28.2%
- -18.8%
- -21.0%
- -9.0%
- 6.1%
- -6.7%
- -6.4%
- -9.9%
- 17.4%
Growth
- −19.5%
- –
- −545.1%
- –
- +1.1%
Financial health
- -0.9×
- 0.01
- 0.9%
- -540.4×
- 5.31
- 5.31
- 0.28
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 28%of 946
Bottom 10%of 872
Bottom 5%of 867
Bottom 5%of 986
What analysts expect
- Average price target
- $36.00
- Range
- $36.00 – $36.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 1, 2026 | -0.36 | -0.35 | −3.4% |
| Feb 27, 2026 | 0.16 | 0.03 | +433.3% |
| Nov 7, 2025 | 0.14 | -0.24 | +158.3% |
| Aug 1, 2025 | 0.07 | -0.23 | +130.4% |
| May 2, 2025 | 0.04 | -0.19 | +121.1% |
| Feb 28, 2025 | 0.04 | -0.31 | +112.9% |
| Nov 8, 2024 | 0.31 | -0.19 | +263.2% |
| Aug 2, 2024 | 0.15 | -0.31 | +148.4% |
News
Fulgent forecasts 2026 revenue of $330M-$340M while narrowing non-GAAP loss to (-$1.65)-(-$1.75) per shareSeeking Alpha · Nov 6, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
44No pass
Benjamin Graham
73Pass
Philip Fisher
41No pass
Peter Lynch
28No pass
Joel Greenblatt
0No pass
Charlie Munger
39No pass
Terry Smith
39No pass
Questions about Fulgent Genetics
Is Fulgent Genetics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Fulgent Genetics AI analysis
What does Fulgent Genetics do?
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. It is in Medical - Diagnostics & Research.
Does Fulgent Genetics pay a dividend?
No. Fulgent Genetics does not pay a dividend at the moment; in 2025 it returned $13.9 million to shareholders by buying back its own shares.
Is Fulgent Genetics stock halal?
No. Fulgent Genetics does not pass our halal screen: its cash and confirmed interest-bearing investments are 48% of its market value, at or above the 33% limit. How we check
How has Fulgent Genetics stock done over the past year?
Down 16.7% over the past twelve months, to $24.66. It traded between $13.79 and $30.85 and is 20.1% below its high.
Who are Fulgent Genetics's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Guardant Health. The peers table on this page compares their profit, growth and price with Fulgent Genetics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.